CAR-T play­er Juno grabs a PhII com­bo drug in $10M add-on deal

Fresh on the heels of a brief but con­tro­ver­sial FDA hold on its lead ther­a­py, Juno has made a small, strate­gic ac­qui­si­tion, buy­ing Boston-based Re­dox Ther­a­pies.

Re­dox is on­ly cost­ing Juno $10 mil­lion up­front, a round­ing er­ror for a fast-mov­ing biotech that is en­gaged in a race to de­vel­op the first CAR-T drug. That plus an un­spec­i­fied set of mile­stones is de­liv­er­ing vipadenant, a small mol­e­cule adeno­sine A2a (A2a) re­cep­tor an­tag­o­nist that “has the po­ten­tial to dis­rupt im­por­tant im­muno­sup­pres­sive path­ways in the tu­mor mi­croen­vi­ron­ment in cer­tain can­cers.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER